Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Fisher Scientific and Newman-Lakka Institute to Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
The collaboration will research diagnostic approaches for personalized cancer treatment.

Thermo Fisher Scientific Inc. and the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center have announced an intended collaboration for research and development of new methods to detect and track circulating biomarkers in blood.

The collaboration will focus on applying Thermo Fisher’s latest ultra-sensitive liquid chromatography-mass spectrometry (LC-MS) instrumentation and technology to develop robust methods for identifying protein biomarkers for a variety of cancers, including breast and prostate cancer as well as tumor-associated blood vessel formation.

“Our challenge and hope is to change the current standard of care, and our collaboration with Thermo Fisher and access to its state-of-the-art instrumentation will accelerate our mission. We hope to be able to provide oncologists with a panel of biomarkers that sense microscopic levels of tumor cells with a simple blood test,” said Charles J. Newman, president of the Newman-Lakka Cancer Foundation.

Newman continued, “The goal is to develop diagnostic tools to make it possible for physicians to check off a panel of biomarkers when patients get regular checkups, so early detection of disease can facilitate effective treatment. Also, the goal is to enable oncologists to monitor the efficacy of treatment with a blood test, rather than waiting 2 months for an MRI and exposing the patients to additional harmful radiation.”

“We’re extremely pleased about this opportunity to collaborate with experts in the search for better cancer treatments,” said Mary Lopez, director of the Thermo Fisher Scientific Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) center that is supporting the collaboration.

Lopez continued, “We anticipate great synergy between Newman-Lakka’s cancer research expertise and our own strength in applying mass spectrometry to biological research and the advancement of personalized medicine will give greater value to both organizations.”

An instrument will be installed at the Genesis Research Institute laboratory adjacent to the Newman Lakka Institute at Tufts Medical Center.

The collaboration’s advanced methods will be conducted at the BRIMS center in Cambridge, Mass., using Thermo Scientific’s triple quadrupole and high resolution accurate mass (HRAM) spectrometry instrumentation, coupled to mass spectrometry immunoassay (MSIA) technology and novel software workflows.

Thermo Fisher’s mass spectrometry instruments are for research use only. Not for use in diagnostic procedures.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Extends Collaboration with University of Birmingham
New Phenome Centre Birmingham, UK to use Thermo Scientific mass spectrometry instruments to advance metabolic phenotyping and metabolomics studies.
Tuesday, May 24, 2016
Transcriptome Profiling Grants Launched
Request for proposal aims to identify promising research projects involving precious samples.
Monday, October 20, 2014
Thermo Fisher Scientific, GSK and Pfizer Collaboration
Thermo Fisher Scientific announces agreement with GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using Next-Generation Sequencing (NGS.)
Thursday, September 25, 2014
Thermo Fisher, Cellectis Enter TAL Nucleases Licensing Agreement
Cellectis and Thermo Fisher Scientific announced that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.
Thursday, June 05, 2014
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos